Global Antimicrobial Susceptibility Testing Market

Antimicrobial Susceptibility Testing Market Size, Share, Growth Analysis, By Test type(Phenotypic testing, genotypic testing, and rapid testing), By End user(Hospitals and diagnostic laboratories, research and academic institutes, and pharmaceutical and biotechnology companies), By Product type(Instruments, reagents and kits, and software and services), By Region - Industry Forecast 2024-2031


Report ID: SQMIG35B2120 | Region: Global | Published Date: April, 2024
Pages: 219 | Tables: 90 | Figures: 76

Antimicrobial Susceptibility Testing Market Insights

Global Antimicrobial Susceptibility Testing Market size was valued at USD 3.79 billion in 2023 and is poised to grow from USD 3.98 billion in 2024 to USD 5.69 billion by 2031, at a CAGR of 5.2% during the forecast period (2024-2031).

Global Antimicrobial Susceptibility Testing (AST) Market is witnessing substantial growth, driven by the increasing prevalence of antimicrobial resistance and the need for effective treatment strategies. Antimicrobial susceptibility testing plays a crucial role in guiding clinicians to select appropriate antimicrobial therapies for patients, ensuring optimal treatment outcomes, and combating the rise of drug-resistant pathogens. The purpose of the market is to provide accurate and timely information on the susceptibility of microorganisms to various antibiotics. AST helps healthcare professionals make informed decisions regarding antibiotic selection, dosage, and treatment duration, aiding in the effective management of infectious diseases. By identifying the most effective antibiotics, AST enables personalized treatment plans, minimizes the risk of treatment failure, and contributes to antimicrobial stewardship efforts. Several key drivers are fueling the growth of the antimicrobial susceptibility testing market. The escalating burden of antimicrobial resistance, resulting in increased morbidity, mortality, and healthcare costs, drives the demand for AST. Additionally, the rise in infectious disease outbreaks, hospital-acquired infections, and the growing awareness about the need for targeted therapies fuel market expansion. The advent of rapid AST methods, automation, and the integration of molecular diagnostics into AST systems are further driving the market growth.

However, limited accessibility to advanced AST methods, particularly in resource-constrained settings, and the high cost associated with implementing sophisticated testing technologies may hinder the market growth. Moreover, the complexity of interpreting test results, challenges in standardizing testing methods, and the time-consuming nature of traditional AST methods pose challenges to market adoption. Key trends in the antimicrobial susceptibility testing market include the development of rapid and accurate AST systems, the integration of artificial intelligence (AI) and machine learning algorithms for data analysis, and the increasing focus on multiplex testing to detect multiple drug resistance patterns simultaneously. The market also presents significant opportunities for growth and innovation. The increasing demand for point-of-care testing, the adoption of automated AST systems in laboratories, and the growing need for personalized medicine in infectious disease management offer attractive prospects. Furthermore, collaborations between diagnostic companies, research institutions, and healthcare organizations can drive advancements in AST technologies and expand market reach.

US Antimicrobial Susceptibility Testing Market is poised to grow at sustainable CAGR for the next forecast year.

$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Antimicrobial Susceptibility Testing Market size was valued at USD 3.60 Billion in 2022 and is poised to grow from USD 3.79 Billion in 2023 to USD 5.68 Billion by 2031, at a CAGR of 5.20% during the forecast period (2024-2031).

Antimicrobial Susceptibility Testing (AST) Market features a competitive landscape with several prominent players vying for market share. Key companies operating in the market are actively engaged in research and development activities to introduce advanced AST systems and technologies. Strategic collaborations, partnerships, and acquisitions are common strategies employed by these players to expand their product portfolio and strengthen their market presence. The market is characterized by intense competition, with a focus on innovation, cost-effectiveness, and accuracy of AST solutions. The presence of established players with strong distribution networks and brand recognition presents barriers to entry for new entrants. 'Thermo Fisher Scientific Inc. (US)', 'Bio-Rad Laboratories, Inc. (US)', 'Danaher Corporation (US)', 'Becton, Dickinson and Company (US)', 'bioMérieux SA (France)', 'Roche Diagnostics (Switzerland)', 'Abbott Laboratories (US)', 'Bruker Corporation (US)', 'Merck KGaA (Germany)', 'Agilent Technologies, Inc. (US)', 'ConvaTec Group plc (UK)', 'Cepheid (US)', 'HiMedia Laboratories Pvt. Ltd. (India)', 'Liofilchem s.r.l. (Italy)', 'Accelerate Diagnostics, Inc. (US)', 'Creative Diagnostics (US)', 'Bio-Rad Laboratories (US)', 'Synbiosis (UK)', 'ELITechGroup (France)', 'QIAGEN N.V. (Germany)'

The rise in antimicrobial resistance is a significant driver for the AST market. The emergence of drug-resistant pathogens poses a severe threat to public health globally. For instance, the increasing prevalence of methicillin-resistant Staphylococcus aureus (MRSA) infections has created a dire need for accurate AST to guide clinicians in selecting appropriate antibiotics for treatment.

Integration of artificial intelligence (AI) and machine learning: The integration of AI and machine learning algorithms in AST data analysis is a growing trend. These technologies can assist in the interpretation of complex datasets and improve the accuracy and speed of AST results interpretation. For example, the AI-powered platform DeepAMR uses machine learning to predict bacterial susceptibility to antibiotics based on genomic data.

North America dominated the AST market, accounting for a substantial market share. The region's dominance can be attributed to several factors, including advanced healthcare infrastructure, well-established laboratory networks, and a strong focus on research and development activities. North America is home to prominent market players, such as bioMérieux, Thermo Fisher Scientific, and BD, which contribute to the region's market leadership. Additionally, the high prevalence of antimicrobial resistance and the proactive measures taken by healthcare organizations to address the issue drive the adoption of AST technologies in the region. With supportive government initiatives, strong investments in healthcare, and a growing emphasis on patient safety, North America holds a significant market share in the AST market.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

logo-images

Feedback From Our Clients

Global Antimicrobial Susceptibility Testing Market

Report ID: SQMIG35B2120

$5,300
BUY NOW GET FREE SAMPLE